# A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)

> **NCT04306887** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)

## Interventions

- **DRUG:** TQ-B3101 capsule

## Key facts

- **NCT ID:** NCT04306887
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-29
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04306887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04306887, "A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04306887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*